GLP-1 FAERS Adverse Events: Safety Signals Explained
You’ve seen news stories about adverse events tied to GLP-1 medications. You may have read about FDA investigations or social media posts from people reporting problems. You want to know if those reports are real and whether they change your risk calculation.
This page exists to translate FDA data for you. It explains what FAERS is, how to read it without panicking or ignoring real signals, and what the major FDA safety reviews have actually found. The goal is to give you the facts so you can make an informed decision with your provider.
What FAERS Is and How to Read It
The FDA Adverse Event Reporting System, or FAERS, now called the FDA Adverse Event Monitoring System (AEMS), is a database of voluntary adverse event reports.[2] Patients, providers, and drug manufacturers can submit reports when someone experiences a side effect or health problem while using a medication.
That’s it. A report in FAERS means someone reported an event. It does not mean the drug caused the event.
The Critical Distinction: Reporting vs. Causation
This is the foundation of understanding FAERS data. A high number of FAERS reports for a drug does not tell you how often an event happens in the population using that drug. It tells you how frequently someone reported that event while taking the drug.
Here’s why that matters: if a condition occurs naturally in 5% of adults with obesity, it will appear in FAERS data for a weight loss drug used by obese adults. Some of those events will happen coincidentally because the population has a high background rate. Others might be caused by the drug. FAERS cannot distinguish between the two.
How FAERS Is Used by the FDA
FAERS is a signal-detection tool. When the FDA sees a sudden spike in reports of a specific event, or an unusual pattern, it flags that as a potential safety signal. This signal then prompts a formal safety review. That review uses epidemiological methods (comparing event rates in treated vs. untreated groups, accounting for background rates, etc.) to determine whether a causal link exists.
Many FAERS signals do not result in regulatory action after formal review. Some do. The major GLP-1 safety reviews discussed below all started with FAERS signals, then were investigated formally.
Major FDA Safety Reviews for GLP-1 Medications
Suicidal Ideation and Self-Harm (2023-2024)
The FDA received reports of suicidal ideation in patients using GLP-1 medications. This prompted a formal safety review.
What the FDA found: In a January 11, 2024 Drug Safety Communication, the FDA said its preliminary evaluation had not found evidence that GLP-1 medications cause suicidal thoughts or actions.[1] The FAERS reports often had limited information and could be influenced by other factors, so they did not show a clear relationship with the medications, and reviews of clinical trials and observational studies did not find an association. Because the number of events was small, the FDA said it could not definitively rule out a small risk and continued to evaluate. In January 2026, the suicidal behavior and ideation warning was removed from the semaglutide weight-management label.[7]
What this means for you: Tell your provider about new or worsening depression or mood changes during any treatment, and get help right away if you have suicidal thoughts (call or text 988). The FDA’s reviews have not found that GLP-1 medications cause these thoughts.
Aspiration During Anesthesia and Surgery (2023)
The FDA has received rare postmarketing reports of pulmonary aspiration in people taking GLP-1 medications who had general anesthesia or deep sedation for elective procedures.[3]
The mechanism: GLP-1 medications slow gastric emptying (the rate at which your stomach releases food into the small intestine). In those reports, people had food or fluid left in the stomach despite following standard preoperative fasting instructions. Under general anesthesia or deep sedation, those residual contents can be aspirated, meaning inhaled into the lungs.
What the FDA did: GLP-1 labeling now includes a warning about pulmonary aspiration during general anesthesia or deep sedation. The label says available data are insufficient to say whether changing fasting instructions or temporarily stopping the medication reduces the risk, and tells patients to inform their healthcare providers before any planned procedure.[3] In 2023, the American Society of Anesthesiologists (ASA) suggested considering holding a weekly GLP-1 dose for one week before an elective procedure, and a daily dose on the day of the procedure.[4] On October 29, 2024, the ASA and four other societies (AGA, ASMBS, ISPCOP, and SAGES) updated that guidance: most people can continue their GLP-1 medication, while people at higher risk (for example, during dose escalation or with ongoing GI symptoms) may be asked to follow a liquid-only diet for 24 hours before the procedure or to postpone it.[8]
What this means for you: Before any elective surgery, inform your surgeon and anesthesiologist that you are taking a GLP-1 medication, and follow their fasting instructions carefully. Your surgical team and the provider who prescribes your GLP-1 decide whether you keep taking it, hold a dose, follow a liquid diet, or reschedule. This is manageable with proper planning. For more detail, see the GLP-1 Surgery and Anesthesia page.
Ileus (Intestinal Obstruction) (2023)
FAERS reports described ileus, meaning an acute or prolonged blockage of intestinal movement, in people taking GLP-1 medications.
What was found: FDA labeling for GLP-1 medications now lists ileus, intestinal obstruction, and severe constipation including fecal impaction among postmarketing reports.[7] Because these come from voluntary reports, the label notes that their frequency cannot be reliably estimated and a causal relationship cannot always be established. Severe constipation that escalates to intestinal obstruction can occur, likely related to GLP-1’s effects on gut motility.
What this means for you: This is distinct from ordinary GLP-1-related constipation, which is common and manageable with hydration and fiber. Ileus is rare and represents severe, persistent intestinal dysfunction. If you develop severe abdominal distension, inability to pass stool for several days despite laxative use, or acute abdominal pain with nausea and vomiting, contact your provider immediately. Your provider should monitor for signs of severe constipation during treatment.
Gastroparesis (2023)
In 2023, researchers published a study in JAMA[5] showing that people using GLP-1 medications for weight loss had a higher risk of gastroparesis (delayed gastric emptying severe enough to cause symptoms) than people using a non-GLP-1 weight-loss medication (bupropion-naltrexone).
This was an observational study, meaning it compared outcomes in two groups but did not randomize people to medication or placebo, so it cannot prove cause and effect on its own. Current labeling warns about severe gastrointestinal adverse reactions and says the medication is not recommended in people with severe gastroparesis.[7]
What this means for you: Severe gastroparesis is a reason labeling advises against GLP-1 use. If you have a history of gastroparesis or chronic stomach problems, your provider should evaluate whether a GLP-1 medication is appropriate. During treatment, delayed stomach symptoms like severe bloating, persistent nausea, or early satiety should be reported to your provider.
Pancreatitis
FAERS reports of pancreatitis have been associated with GLP-1 use since the drugs were first studied. This is one of the longest-standing safety signals.
What the clinical trials showed: Large pivotal trials (STEP 1, SURMOUNT-1) did not show a statistically significant increase in acute pancreatitis in GLP-1 users compared to placebo. The SELECT trial,[6] a cardiovascular outcomes trial in adults with overweight or obesity without diabetes, followed participants for an average of more than three years. In the semaglutide weight-management trials summarized in the FDA label, adjudicated acute pancreatitis occurred at 0.2 cases per 100 patient-years on semaglutide vs less than 0.1 on placebo.[7] Low in absolute terms, but worth monitoring.
What the labeling says: Acute pancreatitis, including rare fatal cases, is included as a warning in GLP-1 medication labeling, and the label says to stop the medication if pancreatitis is suspected.[7] A prior history of pancreatitis is something your provider should weigh carefully when deciding whether the benefits of the medication outweigh the risks for you specifically.
What this means for you: If you have a personal history of pancreatitis, inform your provider before starting. During treatment, pancreatitis presents as severe upper abdominal pain that radiates to the back, often with nausea and elevation of pancreatic enzymes (detectable by blood work). If you develop severe, persistent upper abdominal pain, seek medical attention immediately.
Thyroid Cancer and C-Cell Hyperplasia (Medullary Thyroid Carcinoma Warning)
GLP-1 medications carry a black box warning for medullary thyroid carcinoma (MTC) based on animal studies in rodents.[7] Those studies showed that GLP-1 receptor agonists caused C-cell hyperplasia (overgrowth of thyroid cells) and, in some cases, medullary thyroid carcinoma.
What human data shows: Observational studies in humans have not consistently shown an elevated risk of thyroid cancer in GLP-1 users. The black box warning remains because of the animal findings, even though human epidemiological evidence has not established a causal link.
What the contraindications are: Medullary thyroid carcinoma and Multiple Endocrine Neoplasia type 2 (MEN2) are absolute contraindications. Your provider should screen your personal and family history for these conditions before prescribing.
What this means for you: If you have a personal or family history of medullary thyroid carcinoma or MEN2, you are not a candidate for GLP-1 medications. If you do not have that history, the FDA black box warning still applies, although human evidence has not established an elevated risk. Discuss any personal or family history of thyroid disease with your provider before starting.
What FAERS Does Not Cover: The Compounded Medication Gap
One critical piece of FAERS data to understand: it captures compounded GLP-1 medications poorly.
FAERS is built around FDA-approved medications.[2] Manufacturers of approved drugs are required to send adverse event reports to the FDA, and reports are linked to a specific approved product. Compounded medications are not FDA-approved. Most are prepared by state-licensed compounding pharmacies that are not required to send adverse event reports to the FDA, so reports about compounded products depend largely on patients and providers choosing to submit them.
This means safety signals for compounded GLP-1 products are harder to detect than signals for FDA-approved medications. This is a meaningful distinction you should understand when comparing options.
If you are using a compounded GLP-1 medication, you rely more on the provider who prescribes it to monitor for adverse effects, and on yourself to report problems. You can still report a problem with a compounded product to the FDA through MedWatch.
How to Report an Adverse Event
If you experience a serious side effect or adverse event while taking a GLP-1 medication, you can report it to the FDA.[2]
You can submit a report through MedWatch, the FDA’s adverse event reporting program. You can also contact your provider or the medication manufacturer, and they can submit a report on your behalf.
Reporting is voluntary. Your report will be added to the FDA’s adverse event data (AEMS, formerly FAERS), which means it contributes to signal detection and helps the FDA identify patterns that warrant formal safety reviews.
Citations
[1] FDA. “Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity.” Drug Safety Communication. January 11, 2024. https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type
[2] FDA. “FDA Adverse Event Monitoring System (AEMS) Public Dashboard” (formerly the FAERS Public Dashboard). Content current as of 03/11/2026. https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-public-dashboard
[3] FDA. Prescribing information for Wegovy (semaglutide), section 5.10 “Pulmonary Aspiration During General Anesthesia or Deep Sedation” and section 6.2 postmarketing experience. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[4] American Society of Anesthesiologists Task Force on Preoperative Fasting. “American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.” 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
[5] Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. “Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.” JAMA. 2023;330(18):1795-1797. https://pubmed.ncbi.nlm.nih.gov/37796527/
[6] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
[7] FDA. Prescribing information for Wegovy (semaglutide) injection and tablets. Revised 06/2026 (sections 5.2, 5.6, 6.1, 6.2; Recent Major Changes lists the Suicidal Behavior and Ideation warning as removed 01/2026). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[8] Kindel TL, Wang AY, Wadhwa A, et al.; American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, American Society of Anesthesiologists, International Society of Perioperative Care of Patients with Obesity, Society of American Gastrointestinal and Endoscopic Surgeons. “Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.” Surgery for Obesity and Related Diseases. 2024;20(12):1183-1186. https://pubmed.ncbi.nlm.nih.gov/39482213/ ASA summary (October 29, 2024): https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication. FAERS figures and safety findings on this page are reports and agency summaries as of the dates cited; a FAERS report does not show that a medication caused an event. Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products such as Wegovy. They may differ in formulation, purity, and potency. Results vary. Trial results describe study participants and are not a prediction for any individual. Wegovy is a trademark of Novo Nordisk A/S. Transformation Health is not affiliated with or endorsed by Novo Nordisk.